Seilern Investment Management Ltd Sells 89,960 Shares of Edwards Lifesciences Corporation $EW

Seilern Investment Management Ltd lessened its stake in Edwards Lifesciences Corporation (NYSE:EW) by 13.0% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 600,231 shares of the medical research company’s stock after selling 89,960 shares during the quarter. Edwards Lifesciences accounts for 6.8% of Seilern Investment Management Ltd’s investment portfolio, making the stock its 4th largest position. Seilern Investment Management Ltd’s holdings in Edwards Lifesciences were worth $54,297,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. Hanson & Doremus Investment Management purchased a new stake in Edwards Lifesciences during the first quarter worth about $25,000. JPL Wealth Management LLC acquired a new position in Edwards Lifesciences during the third quarter worth about $25,000. MV Capital Management Inc. purchased a new position in Edwards Lifesciences in the fourth quarter valued at about $26,000. RMG Wealth Management LLC purchased a new position in Edwards Lifesciences in the first quarter valued at about $26,000. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at approximately $27,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 620 shares of Edwards Lifesciences stock in a transaction on Monday, May 18th. The stock was sold at an average price of $81.14, for a total value of $50,306.80. Following the completion of the sale, the vice president owned 40,411 shares of the company’s stock, valued at $3,278,948.54. The trade was a 1.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the transaction, the senior vice president owned 15,334 shares of the company’s stock, valued at $1,319,950.72. The trade was a 3.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 43,539 shares of company stock worth $3,685,364. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Stock Up 0.4%

Shares of NYSE:EW opened at $89.65 on Friday. The company has a quick ratio of 3.63, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $51.62 billion, a P/E ratio of 51.52, a P/E/G ratio of 2.25 and a beta of 0.85. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29. The stock’s fifty day simple moving average is $88.19 and its 200-day simple moving average is $84.08.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities research analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on EW. Robert W. Baird boosted their price target on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. Barclays reaffirmed an “overweight” rating and issued a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. TD Cowen reaffirmed a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Royal Bank Of Canada boosted their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Finally, BTIG Research upped their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.